RELIAJECT^®

Senetek developed and patented Reliaject^®, a unique auto-injector which employs an ultra-fine gauge needle, preset to achieve the appropriate penetration before drug flow occurs, thereby reducing reliance on the patient’s technique for accuracy and safe delivery. Reliaject^® can be adapted for self-administration of a broad range of parenteral drugs including epinephrine, the leading therapeutic agent for the  treatment of anaphylaxis, a severe allergic reaction that occurs in response to food, insect venom or medication.  

The Company believes that the greater ease of use and patient comfort associated with Reliaject^® provides competitive advantages over Epipen^®, the leading autoinjector currently marketed for anaphylaxis, accounting for sales of over $250 million a year in North America alone.  Reliaject^® is well suited to other injectable therapies including Senetek's Invicorp^® for the treatment of ED.   Senetek has entered into a partnership with Ranbaxy Pharmaceuticals Inc., for the commercialization of Reliaject^®.